Comments
Loading...

Century Therapeutics Analyst Ratings

IPSCNASDAQ
Logo brought to you by Benzinga Data
$0.5600
0.048.23%
At close: -
$0.5350
-0.03-4.46%
After Hours: May 16, 7:54 PM EDT
Q1 2025 Earnings were released on Thu May 15th, before the market open
Consensus Rating1
Buy
Highest Price Target1
$24.00
Lowest Price Target1
$2.00
Consensus Price Target1
$9.86

Century Therapeutics Analyst Ratings and Price Targets | NASDAQ:IPSC | Benzinga

Century Therapeutics Inc has a consensus price target of $9.86 based on the ratings of 9 analysts. The high is $24 issued by Canaccord Genuity on March 15, 2024. The low is $2 issued by HC Wainwright & Co. on April 3, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and Chardan Capital on May 16, 2025, April 3, 2025, and March 24, 2025, respectively. With an average price target of $5 between Chardan Capital, HC Wainwright & Co., and Chardan Capital, there's an implied 834.58% upside for Century Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
2
Jan
4
Mar
1
Apr
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Chardan Capital
HC Wainwright & Co.
Piper Sandler
Canaccord Genuity
JP Morgan

1calculated from analyst ratings

Analyst Ratings for Century Therapeutics

Buy NowGet Alert
05/16/2025Buy Now1021.5%Chardan Capital
Geulah Livshits44%
$7 → $6MaintainsBuyGet Alert
04/03/2025Buy Now273.83%HC Wainwright & Co.
Mitchell Kapoor42%
$5 → $2MaintainsBuyGet Alert
03/28/2025Buy Now—Guggenheim
Kelsey Goodwin30%
—ReiteratesBuy → BuyGet Alert
03/24/2025Buy Now1208.41%Chardan Capital
Geulah Livshits44%
$11 → $7MaintainsBuyGet Alert
03/21/2025Buy Now834.58%Guggenheim
Kelsey Goodwin30%
$12 → $5MaintainsBuyGet Alert
03/20/2025Buy Now273.83%Piper Sandler
Edward Tenthoff50%
$4 → $2MaintainsOverweightGet Alert
01/22/2025Buy Now—Guggenheim
Michael Schmidt54%
—ReiteratesBuy → BuyGet Alert
01/22/2025Buy Now834.58%HC Wainwright & Co.
Mitchell Kapoor42%
$5 → $5ReiteratesBuy → BuyGet Alert
12/30/2024Buy Now647.66%Piper Sandler
Edward Tenthoff50%
$12 → $4MaintainsOverweightGet Alert
11/07/2024Buy Now1956.07%Chardan Capital
Geulah Livshits44%
$17 → $11MaintainsBuyGet Alert
11/06/2024Buy Now834.58%HC Wainwright & Co.
Mitchell Kapoor42%
$9 → $5MaintainsBuyGet Alert
08/15/2024Buy Now1582.24%HC Wainwright & Co.
Mitchell Kapoor42%
$11 → $9MaintainsBuyGet Alert
06/17/2024Buy Now2142.99%Piper Sandler
Edward Tenthoff50%
$9 → $12MaintainsOverweightGet Alert
06/04/2024Buy Now1956.07%HC Wainwright & Co.
Mitchell Kapoor42%
$11 → $11ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now1956.07%HC Wainwright & Co.
Mitchell Kapoor42%
$13 → $11MaintainsBuyGet Alert
04/12/2024Buy Now1582.24%Piper Sandler
Edward Tenthoff50%
$10 → $9ReiteratesOverweight → OverweightGet Alert
03/15/2024Buy Now2329.91%HC Wainwright & Co.
Mitchell Kapoor42%
$13 → $13ReiteratesBuy → BuyGet Alert
03/15/2024Buy Now4385.98%Canaccord Genuity
Bill Maughan19%
$22 → $24MaintainsBuyGet Alert
12/07/2023Buy Now2329.91%HC Wainwright & Co.
Mitchell Kapoor42%
$13 → $13ReiteratesBuy → BuyGet Alert
08/28/2023Buy Now834.58%JP Morgan
Eric Joseph43%
$28 → $5DowngradeOverweight → NeutralGet Alert
08/10/2023Buy Now1769.16%Piper Sandler
Edward Tenthoff50%
$14 → $10MaintainsOverweightGet Alert
08/10/2023Buy Now2329.91%HC Wainwright & Co.
Mitchell Kapoor42%
$17 → $13MaintainsBuyGet Alert
08/10/2023Buy Now2890.65%EF Hutton
Tony Butler42%
→ $16ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now3077.57%Chardan Capital
Geulah Livshits44%
$19 → $17MaintainsBuyGet Alert
05/12/2023Buy Now3077.57%HC Wainwright & Co.
Mitchell Kapoor42%
→ $17ReiteratesBuy → BuyGet Alert
04/17/2023Buy Now2890.65%EF Hutton
Tony Butler42%
→ $16MaintainsBuyGet Alert
04/13/2023Buy Now3077.57%HC Wainwright & Co.
Mitchell Kapoor42%
→ $17Reiterates → BuyGet Alert
03/22/2023Buy Now3451.4%Chardan Capital
Geulah Livshits44%
→ $19Reiterates → BuyGet Alert
03/17/2023Buy Now3077.57%HC Wainwright & Co.
Mitchell Kapoor42%
$19 → $17MaintainsBuyGet Alert
03/16/2023Buy Now2890.65%EF Hutton
Tony Butler42%
→ $16Reiterates → BuyGet Alert
02/09/2023Buy Now3451.4%HC Wainwright & Co.
Mitchell Kapoor42%
→ $19Reiterates → BuyGet Alert
01/06/2023Buy Now2890.65%EF Hutton
Tony Butler42%
$18 → $16MaintainsBuyGet Alert
01/06/2023Buy Now2516.82%SVB Leerink
Daina Graybosch42%
$20 → $14MaintainsOutperformGet Alert
01/06/2023Buy Now2516.82%Piper Sandler
Edward Tenthoff50%
$24 → $14MaintainsOverweightGet Alert
01/06/2023Buy Now3451.4%HC Wainwright & Co.
Mitchell Kapoor42%
$25 → $19MaintainsBuyGet Alert
01/05/2023Buy Now3264.49%EF Hutton
Tony Butler42%
→ $18Initiates → BuyGet Alert
12/27/2022Buy Now3451.4%Chardan Capital
Geulah Livshits44%
→ $19Initiates → BuyGet Alert
11/14/2022Buy Now4572.9%HC Wainwright & Co.
Mitchell Kapoor42%
$27 → $25MaintainsBuyGet Alert
10/31/2022Buy Now2703.74%Guggenheim
Kelsey Goodwin30%
→ $15Initiates → BuyGet Alert
05/23/2022Buy Now4946.73%HC Wainwright & Co.
Mitchell Kapoor42%
→ $27Initiates → BuyGet Alert

FAQ

Q

What is the target price for Century Therapeutics (IPSC) stock?

A

The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Chardan Capital on May 16, 2025. The analyst firm set a price target for $6.00 expecting IPSC to rise to within 12 months (a possible 1021.50% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Century Therapeutics (IPSC)?

A

The latest analyst rating for Century Therapeutics (NASDAQ:IPSC) was provided by Chardan Capital, and Century Therapeutics maintained their buy rating.

Q

When was the last upgrade for Century Therapeutics (IPSC)?

A

There is no last upgrade for Century Therapeutics

Q

When was the last downgrade for Century Therapeutics (IPSC)?

A

The last downgrade for Century Therapeutics Inc happened on August 28, 2023 when JP Morgan changed their price target from $28 to $5 for Century Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Century Therapeutics (IPSC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Century Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Century Therapeutics was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.

Q

Is the Analyst Rating Century Therapeutics (IPSC) correct?

A

While ratings are subjective and will change, the latest Century Therapeutics (IPSC) rating was a maintained with a price target of $7.00 to $6.00. The current price Century Therapeutics (IPSC) is trading at is $0.54, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch